凯莱英

002821.SZ

Wind Industry: 医疗保健 > 医药生物 > 生命科学工具和服务Ⅲ > 生命科学工具和服务Ⅳ

公司是一家全球领先、技术驱动型的医药合同定制研发生产(“CDMO”)一站式综合服务商，为全球超1,100家客户提供了药品全生命周期的一站式化学成分生产和控制(“CMC”)服务，高效和高质量的研发与生产服务，加快创新药的临床研究与商业化应用，是全球排名前列的创新药原料药CDMO公司，实现“A+H”双主板上市。公司在天津、吉林、辽宁、上海、江苏，美国Boston、英国Sandwich等多个国家和地区建有研发生产基地，覆盖化学小分子药、化学大分子药(小核酸、多肽和毒素-连接体)、生物药(ADC)、制剂、技术输出及合成生物等诸多业务领域，销售子公司和办事处遍布全球。公司全球员工九千余名，研发人员占比超45%，与全球制药巨头形成了较强的合作粘性，逐步构建起创新药一体化服务生态圈。公司凭借深耕行业超26年积累的行业洞察力、高效的研发生产和卓越服务能力以及良好的行业声誉，成为全球制药产业可靠的首选合作伙伴。公司依托在小分子CDMO领域积累的服务经验、技术积淀与客户资源，积极探索与布局化学大分子CDMO、制剂、临床定制研发(“CRO”)、生物大分子CDMO、工艺技术输出和合成生物技术等新兴业务板块，并取得卓著成效，铸就公司成为专业的全方位创新药一站式定制服务平台。

ESG Score Industry Ranking:
3 / 36 (生命科学工具和服务Ⅲ)

ESG Rating Distribution(生命科学工具和服务Ⅲ)

AAA

25.00%

19.44%

11.11%

BBB

27.78%

16.67%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.44Updated on 2026-10-29

08.4410

Management & Practices Score：5.47Updated on 2026-10-11

05.477

Controversies Score：2.98Updated on 2026-10-29

02.983

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	6.41	3.79	15.43%
Social	7.96	5.15	58.35%
Governance	8.30	6.33	26.22%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(36 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	688114.SH	华大智造	AA	8.82	2.98	5.85	6.92	8.77	8.25
2	300725.SZ	药石科技	AA	8.52	3.00	5.52	8.87	7.33	8.55
3	002821.SZ	凯莱英	A	8.44	2.98	5.47	6.41	7.96	8.30
4	301230.SZ	泓博医药	AA	8.33	2.97	5.36	6.79	8.13	7.13
5	688131.SH	皓元医药	AA	8.31	2.99	5.31	6.30	7.84	7.79
6	688238.SH	和元生物	AA	8.21	2.78	5.43	4.78	8.61	7.58
7	688202.SH	美迪西	AA	8.19	2.97	5.22	5.24	7.93	7.68
8	688222.SH	成都先导	AA	8.11	2.99	5.12	6.02	7.59	7.46
9	300759.SZ	康龙化成	AA	8.05	2.93	5.12	7.67	7.43	6.83
9	603259.SH	药明康德	AA	8.05	2.99	5.07	7.74	6.56	8.46